|
[1] TILG H,CANI PD,MAYER EA. Gut microbiome and liver diseases[J]. Gut,2016,65(12):2035-2044.
|
|
[2] OTTMAN N,HUUSKONEN L,REUNANEN J,et al. Characterization of outer membrane proteome of akkermansia muciniphila reveals sets of novel proteins exposed to the human intestine[J]. Front Microbiol,2016,7:1157.
|
|
[3] DERRIEN M,VAUGHAN EE,PLUGGE CM,et al. Akkermansia muciniphila gen. nov.,sp. nov.,a human intestinal mucin-degrading bacterium[J]. Int J Syst Evol Microbiol,2004,54(Pt 5):1469-1476.
|
|
[4] OUWERKERK JP,van DER ARK K,DAVIDS M,et al. Adaptation of akkermansia muciniphila to the oxic-anoxic interface of the mucus layer[J]. Appl Environ Microbiol,2016,82(23):6983-6993.
|
|
[5] COLLADO MC,DERRIEN M,ISOLAURI E,et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants,adults,and the elderly[J]. Appl Environ Microbiol,2007,73(23):7767-7770.
|
|
[6] CHENG J,RINGEL-KULKA T,HEIKAMP-DE JONG I,et al.Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children[J]. ISME J,2016,10(4):1002-1014.
|
|
[7] BELZER C,de VOS WM. Microbes inside—from diversity to function:The case of Akkermansia[J]. ISME J,2012,6(8):1449-1458.
|
|
[8] DERRIEN M,van BAARLEN P,HOOIVELD G,et al. Modulation of mucosal immune response,tolerance,and proliferation in mice colonized by the mucin-degrader akkermansia muciniphila[J]. Front Microbiol,2011,2:166.
|
|
[9] CANI PD. Human gut microbiome:Hopes,threats and promises[J]. Gut,2018,67(9):1716-1725.
|
|
[10] RIVERA-CHVEZ F,LOPEZ CA,BUMLER AJ. Oxygen as a driver of gut dysbiosis[J]. Free Radic Biol Med,2017,105:93-101.
|
|
[11] ZHANG H,DIBAISE JK,ZUCCOLO A,et al. Human gut microbiota in obesity and after gastric bypass[J]. Proc Natl Acad Sci U S A,2009,106(7):2365-2370.
|
|
[12] PNG CW,LINDN SK,GILSHENAN KS,et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria[J]. Am J Gastroenterol,2010,105(11):2420-2428.
|
|
[13] WANG L,CHRISTOPHERSEN CT,SORICH MJ,et al. Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism[J]. Appl Environ Microbiol,2011,77(18):6718-6721.
|
|
[14] DAO MC,EVERARD A,ARON-WISNEWSKY J,et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity:Relationship with gut microbiome richness and ecology[J]. Gut,2016,65(3):426-436.
|
|
[15] PLOVIER H,EVERARD A,DRUART C,et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med,2017,23(1):107-113.
|
|
[16] EVERARD A,BELZER C,GEURTS L,et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity[J]. Proc Natl Acad Sci U S A,2013,110(22):9066-9071.
|
|
[17] LI J,LIN S,VANHOUTTE PM,et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/-Mice[J]. Circulation,2016,133(24):2434-2446.
|
|
[18] HEYMANN F,HAMESCH K,WEISKIRCHEN R,et al. The concanavalin A model of acute hepatitis in mice[J]. Lab Anim,2015,49(1 Suppl):12-20.
|
|
[19] WANG HX,LIU M,WENG SY,et al. Immune mechanisms of Concanavalin A model of autoimmune hepatitis[J]. World J Gastroenterol,2012,18(2):119-125.
|
|
[20] WU W,LV L,SHI D,et al. Protective effect of akkermansia muciniphila against immune-mediated liver injury in a mouse model[J]. Front Microbiol,2017,8:1804.
|
|
[21] LI J,CHEN K,LI S,et al. Pretreatment with fucoidan from fucus vesiculosus protected against Con A-induced acute liver injury by inhibiting both intrinsic and extrinsic apoptosis[J].PLo S One,2016,11(4):e0152570.
|
|
[22] SONG E,LEE SK,WANG J,et al. RNA interference targeting Fas protects mice from fulminant hepatitis[J]. Nat Med,2003,9(3):347-351.
|
|
[23] ZHENG SJ,WANG P,TSABARY G,et al. Critical roles of TRAIL in hepatic cell death and hepatic inflammation[J]. J Clin Invest,2004,113(1):58-64.
|
|
[24] MALHI H,BARREYRO FJ,ISOMOTO H,et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity[J]. Gut,2007,56(8):1124-1131.
|
|
[25] LUKOVAC S,BELZER C,PELLIS L,et al. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids[J]. m Bio,2014,5(4):e01438-14.
|
|
[26] SHIN NR,LEE JC,LEE HY,et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice[J].Gut,2014,63(5):727-735.
|
|
[27] BAJAJ JS,HEUMAN DM,HYLEMON PB,et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol,2014,60(5):940-947.
|
|
[28] MARA U',MARGARET L,LETICIA M. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflflammation in cirrhotic rats[J]. J Hepatol,2016,64(5):1049-1057.
|
|
[29] CARIO E,GERKEN G,PODOLSKY DK. Toll-like receptor 2controls mucosal inflammation by regulating epithelial barrier function[J]. Gastroenterology,2007,132(4):1359-1374.
|
|
[30] MUCCIOLI GG,NASLAIN D,BCKHED F,et al. The endocannabinoid system links gut microbiota to adipogenesis[J]. Mol Syst Biol,2010,6:392.
|
|
[31] FUSUNYAN RD,QUINN JJ,FUJIMOTO M,et al. Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation[J]. Mol Med,1999,5(9):631-640.
|
|
[32] CIARLO E,HEINONEN T,HERDERSCHEE J,et al. Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo[J]. Sci Rep,2016,6:37944.
|
|
[33] GRANDER C,ADOLPH TE,WIESER V,et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease[J]. Gut,2018,67(5):891-901.
|
|
[34] TILG H,MOSCHEN AR,SZABO G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Hepatology,2016,64(3):955-965.
|
|
[35] BASHIARDES S,SHAPIRO H,ROZIN S,et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab,2016,5(9):782-794.
|
|
[36] KIM S,LEE Y,KIM Y,et al. Akkermansia muciniphila prevents fatty liver disease,decreases serum triglycerides,and maintains gut homeostasis[J]. Appl Environ Microbiol,2020,86(7).
|
|
[37] ASAOKA Y,TERAI S,SAKAIDA I,et al. The expanding role of fish models in understanding non-alcoholic fatty liver disease[J]. Dis Model Mech,2013,6(4):905-914.
|
|
[38] DAI X,WANG B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract,2015,2015:287348.
|
|
[39] ARON-WISNEWSKY J,GABORIT B,DUTOUR A,et al. Gut microbiota and non-alcoholic fatty liver disease:New insights[J]. Clin Microbiol Infect,2013,19(4):338-348.
|
|
[40] JACKSON MA,GOODRICH JK,MAXAN ME,et al. Proton pump inhibitors alter the composition of the gut microbiota[J]. Gut,2016,65(5):749-756.
|
DownLoad: